Lipegfilgrastim: pharmacodynamics and pharmacokinetics for body-weight-adjusted and 6 mg fixed doses in two randomized studies in healthy volunteers.

Role of lipegfilgrastim in the management of chemotherapy-induced neutropenia. Int J Nanomedicine (2015) 1.08

Immunogenicity Assessment of Lipegfilgrastim in Patients with Breast Cancer Receiving Chemotherapy. J Immunol Res (2016) 0.75

Lipegfilgrastim in the management of chemotherapy-induced neutropenia of cancer patients. Biologics (2016) 0.75

Cost-Utility Analysis of Lipegfilgrastim Compared to Pegfilgrastim for the Prophylaxis of Chemotherapy-Induced Neutropenia in Patients with Stage II-IV Breast Cancer. Front Pharmacol (2017) 0.75

Dynamic readers for 5-(hydroxy)methylcytosine and its oxidized derivatives. Cell (2013) 4.16

6-thioguanine nucleotide-adapted azathioprine therapy does not lead to higher remission rates than standard therapy in chronic active crohn disease: results from a randomized, controlled, open trial. Clin Chem (2007) 1.65

Burnout and effort-reward-imbalance in a sample of 949 German teachers. Int Arch Occup Environ Health (2007) 1.34

Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy. BMC Cancer (2013) 1.26

Working conditions, adverse events and mental health problems in a sample of 949 German teachers. Int Arch Occup Environ Health (2007) 1.23

Pharmacokinetic and pharmacodynamic profile of new biosimilar filgrastim XM02 equivalent to marketed filgrastim Neupogen: single-blind, randomized, crossover trial. BioDrugs (2009) 1.20

Correlation between burnout syndrome and psychological and psychosomatic symptoms among teachers. Int Arch Occup Environ Health (2005) 1.18

Incidence of febrile neutropenia and myelotoxicity of chemotherapy: a meta-analysis of biosimilar G-CSF studies in breast cancer, lung cancer, and non-Hodgkin's lymphoma. Onkologie (2009) 1.12

A randomized, double-blind, active control, multicenter, dose-finding study of lipegfilgrastim (XM22) in breast cancer patients receiving myelosuppressive therapy. Breast Cancer Res Treat (2014) 1.07

Association of inosine triphosphatase 94C>A and thiopurine S-methyltransferase deficiency with adverse events and study drop-outs under azathioprine therapy in a prospective Crohn disease study. Clin Chem (2005) 0.97

Analysis of the precision and sensitivity to change of different approaches to assess cartilage loss by quantitative MRI in a longitudinal multicentre clinical trial in patients with knee osteoarthritis. Arthritis Res Ther (2008) 0.92

Epoetin Theta in Anaemic Cancer Patients Receiving Platinum-Based Chemotherapy: A Randomised Controlled Trial. Arch Drug Inf (2010) 0.79

Epoetin Theta with a New Dosing Schedule in Anaemic Cancer Patients Receiving Nonplatinum-Based Chemotherapy: A Randomised Controlled Trial. Arch Drug Inf (2011) 0.79

The polyserine domain of the lysyl-5 hydroxylase Jmjd6 mediates subnuclear localization. Biochem J (2013) 0.79

First-in-human, phase I/IIa dose-escalation and safety study of balugrastim in breast cancer patients receiving myelosuppressive chemotherapy. Cancer Chemother Pharmacol (2015) 0.78

Assessing heterogeneity of peroxisomes: isolation of two subpopulations from rat liver. Methods Mol Biol (2012) 0.77

Phase II dose-finding study of balugrastim in breast cancer patients receiving myelosuppressive chemotherapy. Med Oncol (2015) 0.77

[Return to nursing: half gladly return]. Pflege Z (2004) 0.75